Terms ending in 2041
Every in-force patent on Array Biopharma Inc.'s record whose computed term ends in 2041, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,964,988 | Fused Heterocyclic Compounds as Ret Kinase Inhibitors In force · High confidence | Array Biopharma Inc. | In force | High confidence | |
| US 11,834,453 | SUBSTITUTED PYRIMIDO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS In force · High confidence | Array BioPharma Inc. | In force | High confidence | |
| US 11,932,633 | Kras G12C Inhibitors In force · High confidence | Array Biopharma Inc. | In force | High confidence |
3 of 3 patents shown. Soonest term end first, then patent number.
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.